ArticleScientific reports2025
In Silico exploration of Karanjin for anti-obesity potential through ADMET profiling, network pharmacology, molecular docking, and molecular dynamics simulations.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acute and subacute oral toxicity assessment of Karanjin in Sprague Dawley rats.Toxicology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Obesity is a growing public health concern, particularly in Malaysia, where prevalence rates continue to rise. Despite the availability of pharmacological interventions, existing anti-obesity drugs are often limited by modest efficacy and undesirable side effects. Natural compounds have emerged as promising alternatives, offering multi-target therapeutic potential with improved safety profiles. Karanjin, a furanoflavonoid isolated from Pongamia pinnata, has demonstrated anti-inflammatory and antioxidant activities, but its role in obesity management remains largely unexplored. In this study, an integrated in silico method was employed to explore the anti-obesity potential of Karanjin. Pharmacokinetic profiling indicated favourable absorption, distribution, and toxicity profiles. Network pharmacology analysis identified 145 overlapping targets between Karanjin and obesity-related genes, with enriched significant pathways such as AGE-RAGE signalling, which is implicated in oxidative stress and metabolic dysregulation. Molecular docking against eight hub proteins revealed strong binding affinities, with Karanjin exhibiting superior binding energies compared to reference anti-obesity drugs. Notably, the PIK3CA-Karanjin complex demonstrated the most favourable interaction profile. Confirmed molecular dynamics simulations results in a stable structure of the PIK3CA-Karanjin complex in a span of 100 ns, supported by root mean square deviation (RMSD), radius of gyration (Rg), root mean square fluctuation (RMSF), and solvent accessible surface area (SASA) analyses. Binding free energy calculations using the molecular mechanics Poisson-Boltzmann surface area (MMPBSA) method further validated the thermodynamic favourability of the interaction. Collectively, the findings provide a strong computational foundation supporting the potential of Karanjin as a multi-target candidate for obesity management, warranting further experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.